(Q33237573)

24 July 2017

title

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment (English)

1 reference

24 July 2017

Robert Mader

8

0 references

author name string

Rupert Bartsch

1

1 reference

24 July 2017

Catharina Wenzel

2

1 reference

24 July 2017

Ursula Pluschnig

3

1 reference

24 July 2017

Dagmar Hussian

4

1 reference

24 July 2017

Ursula Sevelda

5

1 reference

24 July 2017

Gabriela Altorjai

6

1 reference

24 July 2017

Gottfried J Locker

7

1 reference

24 July 2017

Christoph C Zielinski

9

1 reference

24 July 2017

Guenther G Steger

10

1 reference

24 July 2017

language of work or name

English

0 references

publication date

26 March 2006

1 reference

24 July 2017

1 reference

24 July 2017

volume

6

1 reference

24 July 2017

page(s)

81

1 reference

The future of fulvestrant ("Faslodex").

24 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Fulvestrant in postmenopausal women with advanced breast cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Tumour marker measurements in the diagnosis and monitoring of breast cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1435763

Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Relationship between bone scintigraphy and tumor markers in patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-81

Tumor marker kinetics in the monitoring of breast cancer

21 January 2018

1 reference

12 December 2020

The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer

1 reference

12 December 2020

Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study

1 reference

12 December 2020

Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer

1 reference

12 December 2020

Carcinoembryonic antigens (CEA) in patients with metastatic breast cancer under endocrine and therapeutic treatment (author's transl)

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-6-81

1 reference

Dimensions Publication ID

24 July 2017

0 references

1 reference

24 July 2017

1 reference